Agilent’s Q2 2026 Earnings: Revenue Rises 10%, Margins Grow, and the Forecast Gets brighter

Executive takeaway

Agilent’s results underscore a durable lift in demand for life sciences tools, with a clear tilt toward margin expansion even as the company grows revenue. The story hinges on a robust top line, a shift toward higher profitability, and an upgraded revenue forecast for the year. For equity observers, the numbers line up with a disciplined approach to both GAAP results and non-GAAP metrics, while the guidance hints at a sustainable operating momentum into the second half of FY26.

Key financials at a glance

• Revenue: $1.83 billion for the second quarter ended April 30, 2026, up 10.0% year over year on a reported basis and up 6.3% on a core basis.
• GAAP operating margin: 21.7%; non-GAAP operating margin: 26.4%, expanded by 130 basis points year over year and 180 basis points sequentially.
• GAAP net income: $339 million; EPS (GAAP) of $1.20, up about 60% from Q2 2025’s $0.75.
• Non-GAAP net income: $423 million; Non-GAAP EPS of $1.49, up 14% year over year.
• Guidance snapshot: FY26 revenue now projected in the range of $7.39 billion to $7.49 billion, representing about 6.3% to 7.8% growth on a reported basis and 4.5% to 6.0% core growth.
• Non-GAAP FY26 EPS: Estimated in the range of $6.00 to $6.10.
• Fiscal Q3 2026 revenue forecast: $1.83 billion to $1.85 billion, with Non-GAAP EPS guidance of $1.48 to $1.50.

The release notes a forward trajectory of continued operational momentum, and the numbers imply a deliberate push to improve profitability even as the top line grows.

Guidance and outlook

The company’s revenue forecast for FY26 is raised, with a mid-point indicating a favorable mix of top-line growth and margin expansion. The non-GAAP EPS target for the year sits at about $6.00 to $6.10, while the non-GAAP operating margin is expected to improve by roughly 85 basis points at the midpoint of core revenue growth. The Q3 2026 revenue range of $1.83–$1.85 billion keeps the growth narrative intact into the next quarter.

What this portends for Agilent and peers

The headline numbers paint a picture of demand resilience in laboratory instrumentation, an area that often benefits from sustained capital budgets in pharma, biotech, and academic research. Margin expansion—driven by efficiencies or favorable product mix—should give investors more comfort that Agilent can translate revenue growth into earnings progress even when the macro backdrop is imperfect.

For sector peers, the message is nuanced, not a mandate. If Agilent can sustain mid-single-digit core growth alongside margin expansion, investors may recalibrate expectations for peers facing similar supply chains, R&D cadence, and customer budgets. The absence of a disclosed EPS consensus or an explicit quarterly earnings surprise in the release means the market will likely look to next prints for a concrete read on how consensus models are adjusting.

Analytical notes and cautionary points

The figures reflect a disciplined approach to both GAAP and non-GAAP accounting, with the company emphasizing the operational momentum behind the uplift in guidance. As with all earnings narratives, the ongoing test is execution: can Agilent maintain its margin trajectory while continuing to grow core revenue in a competitive market for specialized scientific instrumentation?

Conclusion

Agilent’s Q2 2026 report reads like a well-structured equation: revenue up, margins widening, and guidance upward. The stock’s next move might hinge on whether this momentum sustains through the second half of the year and whether peers can match the combination of revenue growth and margin discipline. For now, the revenue forecast looks solid, the EPS narrative strengthened, and the sector will be watching to see if Agilent’s momentum becomes a broader industry trend or a company-specific stretch goal.